• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday

    7/9/24 10:05:05 AM ET
    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Consumer Electronics/Appliances
    Consumer Staples
    Semiconductors
    Technology
    Get the next $ARLO alert in real time by email

    U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.

    Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tuesday's session.

    Keybanc analyst John Vinh maintained NVIDIA with an Overweight and raised the price target from $130 to $180.

    NVIDIA shares gained 3.5% to $132.65 on Tuesday.

    Here are some other big stocks recording gains in today’s session.

    • Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 21.7% to $38.91.
    • Jumia Technologies AG (NYSE:JMIA) shares surged 20.7% to $10.22 after Benchmark initiated coverage on the stock with a Buy rating and $14 price target.
    • Arlo Technologies, Inc. (NYSE:ARLO) shares gained 14.5% to $15.80 after the company's subscription service surpassed 4 million paid accounts.
    • Larimar Therapeutics, Inc. (NASDAQ:LRMR) climbed 9.9% to $9.00.
    • Revolution Medicines, Inc. (NASDAQ:RVMD) gained 9.7% to $43.37.
    • Praxis Precision Medicines, Inc. (NASDAQ:PRAX) shares climbed 7.7% to $45.66.
    • Newegg Commerce, Inc. (NASDAQ:NEGG) rose 7% to $1.1685. Newegg Commerce recently announced that the presale for its tenth annual FantasTech Sales event is now live.
    • Travere Therapeutics, Inc. (NASDAQ:TVTX) gained 6.9% to $9.33.
    • Sezzle Inc. (NASDAQ:SEZL) gained 5.4% to $93.99.
    • Flywire Corporation (NASDAQ:FLYW) shares climbed 5.2% to $17.14
    • Cirrus Logic, Inc. (NASDAQ:CRUS) rose 4.4% to $136.15. Keybanc analyst John Vinh maintained Cirrus Logic with an Overweight and raised the price target from $120 to $155.
    • Micron Technology, Inc. (NASDAQ:MU) rose 3.1% to $134.71. Keybanc analyst John Vinh maintained Micron Technology with an Overweight and increased the price target from $160 to $165.

    Read Next:

    • How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings Report
    Get the next $ARLO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARLO
    $CRUS
    $FLYW
    $JMIA

    CompanyDatePrice TargetRatingAnalyst
    Sezzle Inc.
    $SEZL
    2/12/2026$85.00Buy
    Needham
    Jumia Technologies AG
    $JMIA
    2/6/2026$18.00Overweight
    Cantor Fitzgerald
    Praxis Precision Medicines Inc.
    $PRAX
    2/2/2026$282.00Equal Weight
    Wells Fargo
    Cirrus Logic Inc.
    $CRUS
    2/2/2026$130.00Buy → Hold
    Loop Capital
    Kymera Therapeutics Inc.
    $KYMR
    1/28/2026$133.00Overweight
    Barclays
    Micron Technology Inc.
    $MU
    1/23/2026$350.00 → $500.00Buy
    HSBC Securities
    Micron Technology Inc.
    $MU
    1/22/2026Outperform
    William Blair
    Micron Technology Inc.
    $MU
    1/20/2026$300.00 → $450.00Buy
    TD Cowen
    More analyst ratings

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Liu Teyin M bought $7,821,723 worth of shares (23,200 units at $337.14), increasing direct ownership by 856% to 25,910 units (SEC Form 4)

    4 - MICRON TECHNOLOGY INC (0000723125) (Issuer)

    1/15/26 7:07:13 PM ET
    $MU
    Semiconductors
    Technology

    Large owner Voss Capital, Lp bought $3,203,278 worth of Voting common stock (226,112 units at $14.17) (SEC Form 4)

    4 - Flywire Corp (0001580560) (Issuer)

    1/7/26 5:59:36 PM ET
    $FLYW
    Real Estate

    Director Baker Bros. Advisors Lp bought $172,499,918 worth of shares (2,005,813 units at $86.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    12/11/25 4:19:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Operations Dougherty Justin E sold $429,480 worth of shares (3,000 units at $143.16), decreasing direct ownership by 34% to 5,876 units (SEC Form 4)

    4 - CIRRUS LOGIC, INC. (0000772406) (Issuer)

    2/13/26 5:46:50 PM ET
    $CRUS
    Semiconductors
    Technology

    EVP, General Counsel Thomas Scott exercised 3,239 shares at a strike of $54.65 and sold $458,740 worth of shares (3,239 units at $141.63) (SEC Form 4)

    4 - CIRRUS LOGIC, INC. (0000772406) (Issuer)

    2/13/26 5:45:58 PM ET
    $CRUS
    Semiconductors
    Technology

    Officer Goldsmith Mark A exercised 24,010 shares at a strike of $0.54, increasing direct ownership by 10% to 256,479 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    2/10/26 5:30:31 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Sezzle with a new price target

    Needham initiated coverage of Sezzle with a rating of Buy and set a new price target of $85.00

    2/12/26 7:13:35 AM ET
    $SEZL
    Finance: Consumer Services
    Finance

    Cantor Fitzgerald initiated coverage on Jumia with a new price target

    Cantor Fitzgerald initiated coverage of Jumia with a rating of Overweight and set a new price target of $18.00

    2/6/26 8:11:07 AM ET
    $JMIA
    Catalog/Specialty Distribution
    Consumer Discretionary

    Wells Fargo initiated coverage on Praxis Precision Medicines with a new price target

    Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00

    2/2/26 6:51:57 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Travere Therapeutics Inc.

    SCHEDULE 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)

    2/13/26 6:13:14 AM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arlo Technologies Inc.

    SCHEDULE 13G/A - Arlo Technologies, Inc. (0001736946) (Subject)

    2/12/26 3:20:12 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by Praxis Precision Medicines Inc.

    SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    2/12/26 9:15:03 AM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi

    2/12/26 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on February 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to ten new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 49,200 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the gran

    2/11/26 5:00:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Leadership Updates

    Live Leadership Updates

    View All

    Arlo Technologies Announces Inducement Awards Under NYSE Rule 303A.08

    SAN JOSE, Calif., Feb. 4, 2026 /PRNewswire/ -- Arlo Technologies, Inc. (NYSE:ARLO), a leading smart home security brand, today announced that it had made equity grants to new employees under its 2018 Equity Incentive Plan in accordance with NYSE Rule 303A.08. On February 4, 2026, Arlo's Compensation and Human Capital Committee granted restricted stock units, or RSUs, to three new non-executive employees covering an aggregate of 17,380 shares of the Company's common stock as an inducement for such employees to join the Company. The RSUs vest annually in four equal annual instal

    2/4/26 6:19:00 PM ET
    $ARLO
    Consumer Electronics/Appliances
    Consumer Staples

    Sezzle Announces Chief Financial Officer Transition

    Minneapolis, MN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Sezzle, a purpose-driven digital payment platform, today announced the appointment of Lee Brading as Chief Financial Officer ("CFO"), effective February 1, 2026. Brading will succeed Karen Hartje, who served as CFO and principal financial officer under a Consulting Agreement since November 1, 2025, following her announcement of retirement after nearly eight years as CFO of Sezzle. Hartje will remain engaged as a consultant to ensure an orderly transition.  "Karen has been instrumental in Sezzle's evolution from a private startup to a publicly traded, profitable fintech company," said Char

    1/29/26 4:14:17 PM ET
    $SEZL
    Finance: Consumer Services
    Finance

    Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t

    1/13/26 4:30:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Financials

    Live finance-specific insights

    View All

    Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi

    2/12/26 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the

    2/9/26 4:01:00 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Flywire to Announce Fourth Quarter 2025 Results on February 24, 2026

    BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Flywire Corporation (Flywire) (NASDAQ:FLYW), a global payments enablement and software company, announced that its fourth-quarter financial results will be released after market close on Tuesday, February 24, 2026. Flywire will host a conference call to discuss its fourth-quarter financial results at 5:00 pm ET the same day. Hosting the call will be Mike Massaro, CEO, Rob Orgel, President and COO, and Cosmin Pitigoi, CFO. The conference call will be webcast live from Flywire's investor relations website at https://ir.flywire.com/. A replay will be available on the investor relations website following the call. About FlywireFlywire is a global pay

    2/9/26 8:00:00 AM ET
    $FLYW
    Real Estate

    $ARLO
    $CRUS
    $FLYW
    $JMIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Newegg Commerce Inc.

    SC 13D/A - Newegg Commerce, Inc. (0001474627) (Subject)

    12/17/24 4:37:51 PM ET
    $NEGG
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 7:53:30 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.

    SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)

    11/14/24 5:50:15 PM ET
    $PRAX
    Biotechnology: Pharmaceutical Preparations
    Health Care